Introgen Adenovirus Demonstrates Safety in Hundreds of Patients Biosafety Data Presented in 190 Patients at Annual ASCO Meeting
(PR Newswire)...Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen published results of preclinical studies which indicate a possible application of INGN 201 whereby the human immune system may be directed to attack tumor cells.......INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development....- May 14 4:00 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010514/dam009b.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines